Rocket Pharmaceuticals (RCKT) risk factors, FY2025 10-K

Risks Related to Our Financial Condition and Operating History

1. 01As part of the restructuring, the Company implemented a RIF of approximately 30% of its total workforce, which, along with other planned cost-saving initiatives, is expected to reduce the Company’s 12-month operating expenses by approximately 25%New
2. 02If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any of our product candidates, we may not be successful in commercializing those product candidates if and when they are approved
3. 03The amount of and our ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations and uncertainty38% rewritten
4. 04Our limited operating history may make it difficult for us to evaluate the success of our business to date and to assess our future viability

Risks Related to Capital Needs

1. 05We may need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our licensing activities, product development efforts or other operations
2. 06We have never generated any revenue from product sales and may never be profitable
3. 07maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how

Risks Related to Clinical Development of our Product Candidates

1. 08Our experience with clinical trials has been limited. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at allNew
2. 09If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate planned clinical trials, the occurrence of any of which would harm our business, financial condition, results of operations and prospects
3. 10ability to monitor patients adequately during and after treatment
4. 11Preliminary, interim or topline results in our ongoing clinical studies may not be indicative of results obtained when these studies are completed. Furthermore, success in early clinical studies may not be indicative of results obtained in later studies
5. 12Gene therapy is still a relatively new approach to disease treatment and adverse side effects could develop with our product candidates28% rewritten

Risks Related to Government Regulation

1. 13We have concentrated our R&D efforts to date on a gene therapy platform, and our future success depends on the successful development of viable gene therapy product candidates54% rewritten
2. 14Even though we have obtained orphan designation for certain of our product candidates, we may not be able to realize the benefits of such designation, including potential marketing exclusivity of our product candidates, if approved
3. 15the holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product
4. 16We may seek approval of our product candidates using the FDA’s accelerated approval and the EMA’s conditional approval pathways. While we may utilize trial designs to support accelerated approval, such product candidates may not be subject to faster development or regulatory review timelines23% rewritten
5. 17We have received rare pediatric disease designation for RP-A501 for DD, RP-L102 for FA, and RP-L201 for LAD-I. However, a marketing application for these product candidates, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher65% rewritten
6. 18Even if we successfully complete the necessary preclinical studies and clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate and the approval may be for a narrower indication than we seek
7. 19We may never obtain FDA or EMA approval for any of our product candidates in the U.S. or the EU, and even if we do, we may never obtain approval for or commercialize any of our product candidates in any other jurisdiction, which would limit our ability to realize our full market potential
8. 20Even if we obtain regulatory approval for a product candidate, we will remain subject to ongoing regulatory obligations and continued regulatory scrutiny
9. 21refusing to allow us to enter into supply contracts, including government contracts42% rewritten
10. 22If approved, our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway24% rewritten
11. 23Healthcare legislative reform measures may have a material adverse effect on our business and results of operations

Risks Related to Noncompliance with Applicable Laws or Regulations

1. 24We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities

Risks Related to Manufacturing our Product Candidates

1. 25Products intended for use in gene therapies are novel, complex and difficult to manufacture. We could experience production problems that result in delays in our development or commercialization programs, limit the supply of our products or otherwise harm our business
2. 26Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals
3. 27Product liability lawsuits against us could cause us to incur substantial liabilities and could limit the potential commercialization of any products that we may develop

Risks Related to Commercialization of our Product Candidates

1. 28Our ability to successfully develop and commercialize our product candidates will substantially depend upon the availability of reimbursement for the costs of the resulting drugs and related treatments
2. 29We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our product candidates
3. 30The commercial success of any of our product candidates will depend upon the degree of market acceptance of gene therapy by physicians, patients, third-party payors and others in the medical community
4. 31sufficient third-party payor coverage and reimbursement
5. 32Ethical, legal, and social issues may reduce demand for any gene therapy products for which we obtain marketing approval

Risks Related to Development of our Pipeline and Research and Development Activities

1. 33We may not be successful in our efforts to expand our pipeline of additional product candidates for development
2. 34The success of our R&D activities, clinical testing and commercialization, upon which we primarily focus, is uncertain

Risks Related to Third Parties

1. 35We may not be successful in finding strategic collaborators for continuing development of certain of our product candidates or successfully commercializing our product candidates

Risks Related to Our Intellectual Property

1. 36Our rights to intellectual property for the development and commercialization of our product candidates are subject to the terms and conditions of licenses granted to us by others. If we breach our license agreements, it could have a material adverse effect on our commercialization efforts for our product candidates
2. 37Licenses to additional third-party technology that may be required for our licensing or development programs may not be available in the future or may not be available on commercially reasonable terms, or at all, which could materially harm our business and financial condition
3. 38If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
4. 39We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our development pipeline through acquisitions and in-licenses
5. 40Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
6. 41We may not be able to protect our intellectual property rights throughout the world
7. 42Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
8. 43We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property36% rewritten

Risks Related to our Personnel

1. 44Our business could suffer if it loses the services of, or fails to attract, key personnel40% rewritten
2. 45Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
3. 46We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers

Risks Related to Our Expansion and Growth Plans

1. 47We may need to expand our organization and may experience difficulties in managing this growth, which could disrupt our operations
2. 48We may fail to realize the anticipated benefits of potential acquisitions or business combinations
3. 49merge with, or otherwise enter into a business combination with, another company in which our stockholders would receive cash or shares of the other company on terms that certain of our stockholders may not deem desirable
4. 50Future formations of strategic alliances or joint ventures with third parties could disrupt our business and harm our financial condition and operating results
5. 51litigation or other claims, including claims from employees, customers, former stockholders or other third parties
6. 52Given our commercial relationships outside of the U.S., in particular in the EU, a variety of risks associated with international operations could harm our business25% rewritten
7. 53If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies

Risks Related to Ownership of our Common Stock

1. 54Future sales of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is performing well
2. 55If securities analysts publish negative evaluations of our stock, the price of our stock could decline
3. 56The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for our stockholders
4. 57general economic, industry and market conditions
5. 58RTW, our largest stockholder, may have the ability to significantly influence all matters submitted to stockholders for approval
6. 59Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be stockholders’ sole source of gain
7. 60If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our common stock
8. 61Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
9. 62establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings
10. 63Our internal computer systems, or those of our third-party collaborators or other contractors, may fail or suffer security breaches, which could result in a material disruption of our development programs